Author:
de Bruin Elza C.,Whiteley Jessica L.,Corcoran Claire,Kirk Pauline M.,Fox Jayne C.,Armisen Javier,Lindemann Justin P. O.,Schiavon Gaia,Ambrose Helen J.,Kohlmann Alexander
Publisher
Public Library of Science (PLoS)
Reference33 articles.
1. FDA. Drugs. available from http://www.fda.gov/Drugs/default.htm.
2. EMA. Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection. 2011. available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500108672.pdf.
3. Pharmacodynamic biomarkers: falling short of the mark?;JF Gainor;Clin Cancer Res,2014
4. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background;BR Davies;Mol Cancer Ther,2012
5. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo;R Ribas;Mol Cancer Ther,2015
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献